GlassScriptPhysician profile
Chadi Richeh
NPI 1710214218
$10,305.15
in general payments reported to CMS, 2019-2025
39 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,437 · 2020: $594 · 2021: $1,020 · 2022: $1,877 · 2023: $1,727 · 2024: $2,198 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,367 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,366.59 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,115.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $1,069.68 | 2019-2024 | Afrezza |
| Amgen INC. | $838.08 | 2020-2025 | Tepezza, Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $734.63 | 2019-2025 | |
| Abbott Laboratories | $707.40 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $685.74 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $651.18 | 2023-2025 | |
| Corcept Therapeutics | $432.86 | 2022-2025 | Korlym |
| Radius Health, INC. | $277.77 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.44 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $243.73 | 2023-2025 | |
| Horizon Therapeutics Plc | $206.92 | 2022-2023 | Tepezza |
| Dexcom, INC. | $195.68 | 2019-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $183.15 | 2021-2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $169.47 | 2019-2025 | Farxiga |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valeritas, INC. | $167.83 | 2019 | |
| Insulet Corporation | $158.89 | 2022-2025 | Omnipod |
| Medtronic, INC. | $152.39 | 2021-2025 | Minimed 780g |
| Zealand Pharma US, INC. | $152.08 | 2020-2021 | |
| Cequr Corporation | $134.08 | 2022-2025 | Cequr Simplicity |
| Beta Bionics, INC. | $121.05 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amarin Pharma, INC. | $88.37 | 2019-2021 | |
| Abbvie INC. | $87.18 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $59.58 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Soleno Therapeutics, INC. | $50.98 | 2025 | Vykat Xr |
| Merck Sharp & Dohme LLC | $50.35 | 2019-2022 | |
| Shire North American Group INC | $49.17 | 2019 | |
| Ibsa Pharma INC. | $46.29 | 2022-2023 | Tirosint, Licart |
| Eisai INC. | $41.57 | 2019 | |
| Neurocrine Biosciences, INC. | $23.78 | 2025 | |
| Alexion Pharmaceuticals, INC. | $23.04 | 2019 | |
| Biogen, INC. | $19.38 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.28 | 2022 | |
| Genzyme Corporation | $16.80 | 2022 | |
| Medtronic Minimed, INC. | $15.64 | 2019 | |
| Alvogen INC | $14.71 | 2022 | |
| Recordati_rare_diseases_inc. | $13.59 | 2022 | |
| Eusa Pharma (US) LLC | $13.59 | 2022 | |
| Intuity Medical INC | $11.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chadi Richeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.